ABSTRACT
BACKGROUND & AIMS: Denervation of renal sympathetic nerves (RDN) is an invasive endovascular procedure introduced as an antihypertensive treatment with a potential beneficial effect on insulin resistance (IR). We have previously demonstrated a reduction in blood pressure (BP) six months after RDN, but severe hepatic and peripheral IR, assessed by glucose tracer and two step hyperinsulinemic-euglycemic clamp (HEC), did not improve. The aim of the current study was to evaluate IR and adipokines profiles in relation to BP and arterial stiffness changes two years after RDN. METHODS: In 20 non-diabetic patients with true treatment-resistant hypertension, ambulatory and office BP were measured after witnessed intake of medications prior to, six and 24 months after RDN. Arterial stiffness index (AASI) was calculated from ambulatory BP. Insulin sensitivity (IS) was assessed using an oral glucose tolerance test (OGTT), the Homeostasis Model Assessment (HOMA-IR), HOMA-Adiponectin Model Assessment (HOMA-AD), the Quantitative Insulin Sensitivity Check Index (QUICKI), the Triglyceride and Glucose Index (TyG) and the Leptin-to-Adiponectin Ratio (LAR). These surrogate indices of IS were compared with tracer/HEC measurements to identify which best correlated in this group of patients. RESULTS: All measured metabolic variables and IS surrogate indices remained essentially unchanged two years after RDN apart from a significant increase in HOMA-AD. OGTT peak at 30 min correlated best with reduction in endogenous glucose release (EGR) during low insulin HEC (r = -0.6, p = 0.01), whereas HOMA-IR correlated best with whole-body glucose disposal (WGD) (r = -0.6, p = 0.01) and glucose infusion rate (r = -0.6, p = 0.01) during high insulin HEC. BP response was unrelated to IS prior to RDN. Nocturnal systolic BP and arterial stiffness before RDN correlated positively with a progression in hepatic IR at six-month follow-up. CONCLUSION: IR, adiponectin and leptin did not improve two years after RDN. There was no correlation between baseline IS and BP response. Our study does not support the notion of a beneficial metabolic effect of RDN in patients with treatment resistant hypertension.
Subject(s)
Denervation , Hypertension/surgery , Insulin Resistance/physiology , Kidney/innervation , Time Factors , Adiponectin/blood , Biomarkers/blood , Blood Glucose/metabolism , Blood Pressure , Female , Follow-Up Studies , Glucose Clamp Technique , Glucose Tolerance Test , Health Status Indicators , Humans , Hypertension/blood , Insulin/blood , Leptin/blood , Male , Middle Aged , Postoperative Period , Treatment Outcome , Vascular StiffnessABSTRACT
The main aim of the study was to determine the influence of genetic factors on the serum 25-hydroxyvitamin D response to vitamin D supplementation. The main outcome measure was an increase in serum 25-hydroxyvitamin D after vitamin D supplementation. The patients are part of a randomized controlled trial in individuals with prediabetes assigned to 20 000 IU of vitamin D3 per week or placebo for 12 months. A total of 484 subjects were included in the analyses and genotyped for single nucleotide polymorphisms in the DBP, DHCR7, CYP2R1, and CYP24A1 genes. Single nucleotide polymorphisms from all 4 selected genes were significantly related to baseline serum 25-hydroxyvitamin D concentrations with differences between major and minor homozygote genotypes ranging from 4.4 to 19.2 nmol/l. In the subjects given vitamin D, those with genotypes with the highest baseline 25-hydroxyvitamin D concentration also had the highest 25-hydroxyvitamin D concentration after 12 months, and the increase (delta) in 25-hydroxyvitamin D was significantly related to 3 of the single nucleotide polymorphisms. The increase in serum 25-hydroxyvitamin D was also higher in lean vs. obese subjects, and higher in those with low baseline 25-hydroxyvitamin D concentrations. When combining these 3 factors in a linear regression model, the predicted (and observed) difference in 25-hydroxyvitamin D increase between high and low responders to the supplementation was approximately 60 nmol/l. In conclusion, due to genetic, body mass, and baseline 25-hydroxyvitamin D differences, there are huge individual variations in the serum 25-hydroxyvitamin D response to vitamin D supplementation that could be of clinical importance.
Subject(s)
Body Mass Index , Dietary Supplements , Genotype , Vitamin D/analogs & derivatives , Age Factors , Female , Humans , Male , Middle Aged , Placebos , Polymorphism, Single Nucleotide/genetics , Sex Characteristics , Vitamin D/bloodABSTRACT
Medulloblastomas are the most common malignant brain tumors in children. They express high levels of COX-2 and produce PGE2, which stimulates tumor cell proliferation. Human cytomegalovirus (HCMV) is prevalent in the human population and encodes proteins that provide immune evasion strategies and promote oncogenic transformation and oncomodulation. In particular, HCMV induces COX-2 expression; STAT3 phosphorylation; production of PGE2, vascular endothelial growth factor, and IL-6; and tumor formation in vivo. Here, we show that a large proportion of primary medulloblastomas and medulloblastoma cell lines are infected with HCMV and that COX-2 expression, along with PGE2 levels, in tumors is directly modulated by the virus. Our analysis indicated that both HCMV immediate-early proteins and late proteins are expressed in the majority of primary medulloblastomas. Remarkably, all of the human medulloblastoma cell lines that we analyzed contained HCMV DNA and RNA and expressed HCMV proteins at various levels in vitro. When engrafted into immunocompromised mice, human medulloblastoma cells induced expression of HCMV proteins. HCMV and COX-2 expression correlated in primary tumors, cell lines, and medulloblastoma xenografts. The antiviral drug valganciclovir and the specific COX-2 inhibitor celecoxib prevented HCMV replication in vitro and inhibited PGE2 production and reduced medulloblastoma tumor cell growth both in vitro and in vivo. Ganciclovir did not affect the growth of HCMV-negative tumor cell lines. These findings imply an important role for HCMV in medulloblastoma and suggest HCMV as a novel therapeutic target for this tumor.
Subject(s)
Brain Neoplasms/virology , Cytomegalovirus/isolation & purification , Medulloblastoma/virology , Adult , Animals , Antiviral Agents/pharmacology , Brain Neoplasms/drug therapy , Celecoxib , Cell Line, Tumor , Child , Child, Preschool , Cyclooxygenase 2 Inhibitors/pharmacology , Cytomegalovirus/drug effects , Cytomegalovirus/pathogenicity , Cytomegalovirus/physiology , Dinoprostone/biosynthesis , Female , Ganciclovir/analogs & derivatives , Ganciclovir/pharmacology , Humans , Infant , Male , Medulloblastoma/drug therapy , Mice , Mice, Nude , Middle Aged , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Valganciclovir , Virus Replication/drug effects , Xenograft Model Antitumor Assays , Young AdultABSTRACT
BACKGROUND: Acute liver failure (ALF) is characterized haemodynamically by a progressive hyperdynamic circulation. The pathophysiological mechanism is unknown, but impaired contractility of vascular smooth muscle may play an important role. The aim of this study was to evaluate the vascular response to stimulation with norepinephrine and angiotensin II in endothelium-denuded femoral artery rings. METHODS: Norwegian Landrace pigs weighing 27.1 +/- 0.5 kg (mean +/- sx (standard error of the mean)) were used. ALF was induced by performing a portacaval shunt followed by ligation of the hepatic arteries (n = 6). Sham-operated animals served as controls (n = 5). Cumulative isometric concentration contraction curves were obtained after in vitro stimulation of the femoral artery rings with either angiotensin II (10(-13) - 10(-5) mol/L) or norepinephrine (10(-13) - 10(-3) mol/L). RESULTS: Pigs suffering from ALF developed a hyperdynamic circulation with an increased cardiac index (P = 0.017) and decreased systemic vascular resistance index (P = 0.015). Studies of the hind leg revealed a decreased vascular resistance index and increased blood flow compared to sham-operated controls (P = 0.003 and P = 0.01, respectively). Angiotensin II caused a concentration-dependent contraction of the arterial segments, with no significant differences in vascular responses between the two groups. Maximum force generated did not differ (55 +/- 7 versus 56 +/- 7 mN, P = 0.95). Furthermore, there were no differences for norepinephrine in the cumulative concentration-response curves and the maximum contractile force was not significantly different (87 +/- 8 versus 93 +/- 16 mN, P = 0.55). CONCLUSIONS: This study documents for the first time that there are no signs of endothelium-independent peripheral vascular hyporesponsiveness to angiotensin II and norepinephrine in pigs with ALF.
Subject(s)
Femoral Artery/drug effects , Femoral Artery/physiology , Liver Failure, Acute/complications , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Vasoconstriction/drug effects , Angiotensin II/pharmacology , Animals , Disease Models, Animal , Female , Heart Function Tests , Hemodynamics/physiology , Norepinephrine/pharmacology , Probability , Random Allocation , Sensitivity and Specificity , Swine , Vasodilation/drug effectsABSTRACT
High-dose methotrexate (HD-MTX) is widely used in combination chemotherapy and can be handled without life-threatening toxicity in combination with leucovorin (LV) rescue. However, in an experimental animal model for testing of short-term HD-MTX effects in anesthetized rats, the authors previously demonstrated intolerable toxicity and death within a few hours in some animals. Serum levels were below levels routinely found in patients on HD-MTX treatment. This study was aimed at disclosure of possible mechanisms for acute toxicity of MTX in rats. The previously determined maximum tolerated dose of 5 g/kg MTX was used as the test dose. The animals that died showed sudden reduction in heart rate and blood pressure. LV, 1 g/kg infused immediately prior to MTX, changed MTX elimination kinetics, but did not change the acute toxicity. The data of this study together with additional evidence obtained in the experimental model, suggest that MTX acute toxicity may not be related to its antiproliferative effect, but rather to perturbation of endothelial cell and platelet function.
Subject(s)
Antimetabolites, Antineoplastic/toxicity , Leucovorin/pharmacology , Maximum Tolerated Dose , Methotrexate/toxicity , Animals , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/blood , Arrhythmias, Cardiac/chemically induced , Kidney/drug effects , Liver/drug effects , Male , Methotrexate/administration & dosage , Methotrexate/blood , Rats , Rats, Wistar , Survival RateABSTRACT
Methotrexate (MTX) is a clinically important cytostatic antifolate. The study describes the acute effects of maximum tolerated doses of MTX or its major metabolite 7-hydroxymethotrexate (7-OH-MTX) on the ultrastructure of rat liver and kidneys. The ultrastructural changes in rats receiving MTX or 7-OH-MTX were, in principle, indistinguishable and their severity and extension increased with time of survival or doses of medication. All lesions were focal, microvascular, or parenchymal. Microvascular changes were more severe in nature when blood cells were present. The endothelial cells were swollen with loss of pinocytotic vesicles, their luminal plasma membrane formed blebs or were disrupted. Partly detached endothelial cells or deendothelialized areas, various types of white blood cells, in particular, neutrophil granulocytes, were observed in the microcirculation. Single platelets or small platelet aggregates were found either in the lumen or adhering to deendothelialized areas of injured endothelial cells. Hepatocytes exhibited steatosis, edema, and manifest single cell necrosis. There were also nuclear changes, marked proliferation of smooth endoplasmatic reticulum, increased amounts of intracellular lipid vacuoles, and a decrease in glycogen particles in hepatocytes. The kidney presented the major changes in the tubules and in the interstitial part. MTX and 7-OH-MTX acute toxicity may primarily be related to microvascular perturbation.
Subject(s)
Antineoplastic Agents/toxicity , Endothelium, Vascular/drug effects , Kidney/blood supply , Liver/blood supply , Methotrexate/toxicity , Animals , Dose-Response Relationship, Drug , Endothelium, Vascular/ultrastructure , Hepatocytes/drug effects , Hepatocytes/ultrastructure , Kidney/ultrastructure , Liver/ultrastructure , Male , Maximum Tolerated Dose , Methotrexate/analogs & derivatives , Microcirculation/drug effects , Microcirculation/ultrastructure , Rats , Rats, WistarABSTRACT
PURPOSE: After more than 50 years of methotrexate (MTX) treatment of acute lymphoblastic leukaemia (ALL), it is currently believed that as long as dose escalations are followed by adequate leucovorin rescue guided by monitoring MTX serum concentrations, hydration and urinary alkalinization, high-dose MTX (HD-MTX) can be tolerated without life-threatening toxicity. However, our recent experimental animal studies of the major metabolite of MTX, 7-OH-MTX, indicate that this concept may have some limitations. Animals with levels of 7-OH-MTX of 1 mM, which is below the levels routinely found in patients on HD-MTX, demonstrate intolerable toxicity and some animals die within 8 h. Electron microscopy indicates that endothelial cell and platelet functions are perturbed. Since animal data are lacking, and interspecies differences not known, we wanted to investigate the maximum tolerated doses of MTX and 7-OH-MTX in a rat model of short-term effects. The maximum tolerated dose was chosen instead of LD(50) for reasons of animal welfare. METHODS: We infused MTX and 7-OH-MTX into anaesthetized male Wistar rats and monitored the animals for 8 h. The drugs were given as a bolus plus continuous infusion. The dose-finding ranges were 1.8 11.3 g/kg MTX and 0.1-1.2 g/kg 7-OH-MTX. RESULTS: The maximum tolerated dose was between 3 and 5 g/kg for MTX and lower than 0.1 g/kg for 7-OH-MTX. The mean serum concentrations of MTX and 7-OH-MTX in animals that did not survive the 8-h period were 21.9 and 1.6 mM, respectively. The animals that received the highest MTX or 7-OH-MTX doses and concentrations died after sudden reductions in heart rate and blood pressure. CONCLUSIONS: We demonstrated a lower maximum tolerated dose of 7-OH-MTX than of MTX in rats after 8 h. The 7-OH-MTX concentrations were in the therapeutic range after HD-MTX. If the rat/human interspecies differences are not large, our data may indicate that HD-MTX regimens should not be further dose intensified, due not so much to the effects of MTX as to those of 7-OH-MTX.
Subject(s)
Methotrexate/analogs & derivatives , Methotrexate/toxicity , Animals , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Electrocardiography/drug effects , Heart Rate/drug effects , Male , Methotrexate/administration & dosage , Methotrexate/pharmacokinetics , Models, Biological , Rats , Rats, WistarABSTRACT
A simplified method for the preparation and long-term cultivation of granulosa-luteal cells in serum-free medium is described. The cells were harvested from women undergoing in-vitro fertilization, enriched by sedimentation and dissociated by enzymatic treatment. We demonstrated, by introducing a synthetic serum replacement (SSR2), that these primary cell cultures cultivated in monolayers on an extracellular matrix may be used in experiments exceeding 7 days with low cell loss and cell death. No adverse effect on progesterone production was found. There was a high diversity in progesterone production between cells from individual patients. After several days in culture, the cells were challenged with human chorionic gonadotrophin which revived the rapidly decreasing progesterone production. We were unable to demonstrate an increase in cell number after 7 days of cultivation when the cells were grown in medium supplemented with either serum or SSR2. The mitogens epidermal growth factor and basic fibroblast growth factor had no influence on proliferation. We also found that the present method prevents leukocyte contamination in the granulosa-luteal cell cultures. Compared with the common method based on the enrichment of granulosa-luteal cells on a density gradient (Ficoll/Percoll), this method saves time, labour and expense, in addition to augmenting purity.
Subject(s)
Granulosa Cells/cytology , Luteal Cells/cytology , Adult , Cell Count , Cell Culture Techniques/methods , Cell Division , Cell Survival , Culture Media, Serum-Free , Female , Fertilization in Vitro , HumansABSTRACT
To elucidate mechanisms for methotrexate (MTX)-induced renal and hepatic toxicity, we investigated the acute effects of bolus plus continuous infusion of up to 0.4 g/kg 7-hydroxymethotrexate (7-OH-MTX) in the rat. We demonstrate for the first time in any species the occurrence of acute lethal toxicity within a few hours after 7-OH-MTX administration. Serum concentrations of 7-OH-MTX measured at the time of death were 1.4 mM (mean), about one-half of those achieved in some patients after infusion of high-dose MTX (HD-MTX) in the clinic. The data suggest an approximate LD50 (the dose lethal to 50% of the study population) of 0.3 g/kg and a steep dose/lethality curve for 7-OH-MTX. Moreover, acute renal and hepatic toxicity occurred as evidenced by severe morphological findings and increased serum levels of creatinine and liver transaminases. In all rats subjected to continuous infusion of 7-OH-MTX, yellow microscopic precipitations were apparent in the kidney tubules. Crystallization was also seen in bile ducts of the liver in some of the rats. These results further support that the formation of 7-OH-MTX is disadvantageous and that reported attempts to prevent its formation during MTX treatment are warranted.
Subject(s)
Folic Acid Antagonists/toxicity , Kidney/drug effects , Liver/drug effects , Methotrexate/analogs & derivatives , Animals , Folic Acid Antagonists/administration & dosage , Folic Acid Antagonists/analysis , Folic Acid Antagonists/blood , Infusions, Intravenous , Injections, Intravenous , Kidney/pathology , Kidney Glomerulus/drug effects , Kidney Glomerulus/ultrastructure , Kidney Tubules/chemistry , Kidney Tubules/pathology , Kidney Tubules/ultrastructure , Lethal Dose 50 , Liver/pathology , Male , Methotrexate/administration & dosage , Methotrexate/analysis , Methotrexate/blood , Methotrexate/toxicity , Rats , Survival Rate , Time FactorsABSTRACT
The effects of diltiazem (DIL), verapamil (VRP) and Ca2+ on the accumulation of methotrexate (MTX) were investigated in isolated rat hepatocytes. At the physiological 2 mM Ca2+, the calcium-channel blockers DIL (100 microM) and VRP (50 microM) significantly reduced the hepatocellular accumulation of MTX. By increasing the Ca2+ concentration to 7 mM control MTX levels (at 2 mM Ca2+) were restored with VRP, and resulted in MTX levels above the controls for DIL. Ca2+ at 7 mM significantly enhanced MTX accumulation in the hepatocyte suspensions after 60 min. The concentration time curves for MTX indicated that for the first 10 min influx was the dominating process. Dixon plot analysis of this uptake phase revealed Ki values of 140 microM for DIL and 75 microM for VRP. The data suggested that DIL was a non-competitive, and VRP a competitive inhibitor of MTX influx. Hence, the inhibitory effect on MTX accumulation mediated by DIL and VRP could be due to different mechanisms.
Subject(s)
Calcium Channel Blockers/pharmacology , Calcium/pharmacology , Liver/metabolism , Methotrexate/metabolism , Animals , Biological Transport/drug effects , Diltiazem/pharmacology , Male , Rats , Rats, Wistar , Verapamil/pharmacologyABSTRACT
BACKGROUND: Methotrexate (MTX) is extensively used in different combination chemotherapy regimens. More knowledge about interactions and their mechanisms in target cancer cells and normal cells is needed to improve therapeutic efficacy and reduce toxicity. MATERIALS AND METHODS: The effect of verapamil (VRP), vinblastine (VBL), taurocholate (TAURO) and bromosulfophthalein (BSP) on MTX transport were studied in freshly isolated rat hepatocytes. RESULTS: During 60 min, 50 microM VRP decreased the hepatocellular MTX accumulation with 29%; whereas 100 microM BSP reduced MTX entrance with 15%. 100 microM VBL and 100 microM TAURO reduced the intracellular accumulation of MTX with 36% and 23%, respectively. VRP and BSP appeared to be selective MTX influx blockers, whereas VBL and TAURO inhibited both MTX influx and efflux, however, with major inhibition on MTX influx. Dixon plot analyses for TAURO and BSP were suggestive of competitive inhibition, giving inhibition constants (Ki) values of 105 microM for TAURO, and 800 microM for BSP. CONCLUSION: The data demonstrate for the first time a selective inhibitory effect of VRP upon MTX influx in isolated rat hepatocytes, whereas BSP, a potent MTX efflux inhibitor in malignant cells fails to achieve this effect in the normal cell type here investigated.